RxDoctor Payments Data

Arlene Donowitz, MD

Internal Medicine · Chattanooga, TNNPI 1548247109

Payments from drug & device makers

$6,791in general payments, 2019–2025

Across 437 payments — averaging $15.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$951
  • Pfizer$750
  • AbbVie$712
  • GSK$604
  • Johnson & Johnson$504
  • Novartis$396
  • plus $3K from 33 others

What the payments were for

  • Food & beverage$6,65998%
  • Education$821%
  • Other$501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,791 in reported general payments places this provider in the 85th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$294,273
Medicare patients
464
Services billed
5,970

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide126$150,003
OzempicSemaglutide93$126,534
EliquisApixaban78$96,444
JardianceEmpagliflozin35$41,070
XareltoRivaroxaban41$37,587
JanuviaSitagliptin Phosphate22$33,038
TrulicityDulaglutide19$28,671
FarxigaDapagliflozin Propanediol32$25,902
Teriparatide12$25,637
MyrbetriqMirabegron17$17,067
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$13,390
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$11,909
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$10,480
Breo ElliptaFluticasone/Vilanterol19$9,778
Atorvastatin Calcium585$7,490

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$87$178,673145 claims
Novo NordiskOzempic$951$126,53493 claims
PfizerEliquis$750$96,44478 claims
Boehringer IngelheimJardiance$62$41,07035 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$191$39,95762 claims
Johnson & JohnsonXarelto$504$37,58741 claims
MerckJanuvia$59$33,03822 claims
GSKTrelegy Ellipta, Breo Ellipta$604$23,16833 claims
Astellas Pharma US IncMyrbetriq$372$17,06717 claims
AbbVieSynthroid$712$5,43972 claims
Sanofi-aventis U.S. LLCLantus$69$4,71715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →